With Ozempic’s New Indication, Novo Nordisk Dominates the GLP-1 Space
Novo Nordisk Strengthens Its GLP-1 Market Dominance with Ozempic’s Latest Approval
Expanding Ozempic’s Role in Diabetes and Weight Management
Novo Nordisk continues to lead the GLP-1 receptor agonist market, further solidifying its dominance with the latest approval of Ozempic. Fueled by semaglutide’s cardiovascular benefits, Ozempic is gaining traction beyond diabetes management, with increasing evidence supporting its efficacy in obesity, cardiovascular health, and kidney disease.
For More : https://www.delveinsight.com/b....log/ozempic-for-chro